Reactivity to N-terminally truncated GAD65(96-585) identifies GAD autoantibodies that are more closely associated with diabetes progression in relatives of patients with type 1 diabetes

Diabetes

Volumn 64, Issue 9, 2015, Pages 3247-3252

  Williams, Alistair J K ^a   Lampasona, Vito ^b   Wyatt, Rebecca ^a   Brigatti, Cristina ^b   Gillespie, Kathleen M ^a   Bingley, Polly J ^a   Achenbach, Peter ^c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE DECARBOXYLASE 65 ANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY; AUTOANTIBODY; GAD65 (96-585); GLUTAMATE DECARBOXYLASE; PEPTIDE FRAGMENT;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; GENOTYPE; HLA SYSTEM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH ORGANIZATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; FAMILY; GENETICS; IMMUNOLOGY; INFANT; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

ADOLESCENT; ADULT; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; FAMILY; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; INFANT; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84947344265     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1694     Document Type: Article

References (20)

1. Bingley PJ. Clinical applications of diabetes antibody testing. J Clin Endo-crinol Metab 2010;95:25-33
2. Liu E, Eisenbarth GS. Accepting clocks that tell time poorly: fluid-phase versus standard ELISA autoantibody assays. Clin Immunol 2007;125:120-126
3. Williams AJ, Lampasona V, Schlosser M, et al.; Participating Laboratories. Detection of antibodies directed to the N-terminal region of GAD is dependent on assay format and contributes to differences in the specificity of GAD autoantibody assays for type 1 diabetes. Diabetes. 13 May 2015 [Epub ahead of print]. DOI: 10.2337/db14-1693
4. Long AE, Gillespie KM, Rokni S, Bingley PJ, Williams AJ. Rising incidence of type 1 diabetes is associated with altered immunophenotype at diagnosis. Diabetes 2012;61:683-686
5. Bingley PJ, Williams AJ, Gale EA. Optimized autoantibody-based risk assessment in family members. Implications for future intervention trials. Diabetes Care 1999;22:1796-1801
6. Long AE, Gillespie KM, Aitken RJ, Goode JC, Bingley PJ, Williams AJ. Humoral responses to islet antigen-2 and zinc transporter 8 are attenuated in patients carrying HLA-A∗24 alleles at the onset of type 1 diabetes. Diabetes 2013;62:2067-2071
7. Bonifacio E, Yu L, Williams AK, et al. Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for National Institute of Diabetes and Digestive and Kidney Diseases Consortia. J Clin Endocrinol Metab 2010;95:3360-3367
8. Bingley PJ, Bonifacio E, Williams AJ, Genovese S, Bottazzo GF, Gale EA. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 1997;46:1701-1710
9. Gillespie KM, Valovin SJ, Saunby J, et al. HLA class II typing of whole genome amplified mouth swab DNA. Tissue Antigens 2000;56:530-538
10. Hoppu S, Ronkainen MS, Kulmala P, Akerblom HK, Knip M; Childhood Diabetes in Finland Study Group. GAD65 antibody isotypes and epitope recognition during the prediabetic process in siblings of children with type I diabetes. Clin Exp Immunol 2004;136:120-128
11. Bonifacio E, Lampasona V, Bernasconi L, Ziegler AG. Maturation of the humoral autoimmune response to epitopes of GAD in preclinical childhood type 1 diabetes. Diabetes 2000;49:202-208
12. Mayr A, Schlosser M, Grober N, et al. GAD autoantibody affinity and epitope specificity identify distinct immunization profiles in children at risk for type 1 diabetes. Diabetes 2007;56:1527-1533
13. Richter W, Shi Y, Baekkeskov S. Autoreactive epitopes defined by diabetes-associated human monoclonal antibodies are localized in the middle and C-terminal domains of the smaller form of glutamate decarboxylase. Proc Natl Acad Sci USA 1993;90:2832-2836
14. 125I-labelled recombinant GAD65 produced in yeast. Clin Chim Acta 1996;256:175-188
15. Payton MA, Hawkes CJ, Christie MR. Relationship of the 37, 000-and 40, 000-M(r) tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). J Clin Invest 1995; 96:1506-1511
16. Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 2007;104:17040-17045
17. Bender C, Schlosser M, Christen U, Ziegler AG, Achenbach P. GAD auto-antibody affinity in schoolchildren from the general population. Diabetologia 2014;57:1911-1918
18. Desai M, Williams AJK, Horton VA, et al. GAD65 autoantibody titres at diagnosis in latent autoimmune diabetes in adults (LADA) differ from type 1 diabetes (T1D) and together with epitope specificity predict insulin requirement. Diabetologia 2004;47(Suppl. 1):A186-A187
19. Brooking H, Ananieva-Jordanova R, Arnold C, et al. A sensitive non-isotopic assay for GAD65 autoantibodies. Clin Chim Acta 2003;331:55-59
20. Miao D, Guyer KM, Dong F, et al. GAD65 autoantibodies detected by electrochemiluminescence assay identify high risk for type 1 diabetes. Diabetes 2013;62:4174-4178